Maria Cristina Volpato

Maria Cristina Volpato

Auto-generated profile, based on publicly available information

Maria Cristina Volpato

Department of Physiological Sciences, Piracicaba Dental School, University of Campinas - UNICAMP, Piracicaba, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2012 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
Eneida De PaulaEneida De Paula
Eneida De Paula
CCCíntia Ms Cereda
Cíntia Ms Cereda
LFLeonardo Fernandes Fraceto
Leonardo Fernandes Fraceto
Daniele Ribeiro de AraújoDaniele Ribeiro de Araújo
Daniele Ribeiro de Araújo
Michelle Franz-MontanMichelle Franz-Montan
Michelle Franz-Montan
Francisco GroppoFrancisco Groppo
Francisco Groppo
Introduction: One of the most common strategies for pain control during and after surgical procedures is the use of local anesthetics. Prolonged analgesia can be safely achieved with drug delivery systems suitably chosen for each local anesthetic agent. Areas covered: This review considers drug delivery formulations of local anesthetics designed to prolong the anesthetic effect and decrease toxicity. The topics comprise the main drug delivery carrier systems (liposomes, biopolymers, and cyclodextrins) for infiltrative administration of local anesthetics. A chronological review of the literature is presented, including details of formulations as well as the advantages and pitfalls of each carrier system. The review also highlights pharmacokinetic data on such formulations, and gives an overview of the clinical studies published so far concerning pain control in medicine and dentistry. Expert opinion: The design of novel drug delivery systems for local anesthetics must focus on how to achieve higher uploads of the anesthetic into the carrier, and how to sustain its release. This comprehensive review should be useful to provide the reader with the current state-of-art regarding drug delivery formulations for local anesthetics and their possible clinical applications.

22 May 2014 in International Endodontic Journal
Verified
Journal Article
Closed access
PDF file
MMM. R. F. P. Monteiro
M. R. F. P. Monteiro
FGF. C. Groppo
F. C. Groppo
FHFrancisco Haiter-Neto
Francisco Haiter-Neto
MVM. C. Volpato
M. C. Volpato
JAJ. F. A. Almeida
J. F. A. Almeida

7 May 2014 in Journal of Liposome Research
Verified
Journal Article
Closed access
Michelle Franz-MontanMichelle Franz-Montan
Michelle Franz-Montan
DBDaniela Baroni
Daniela Baroni
GBGiovana Brunetto
Giovana Brunetto
VSViviane Roberta Vieira Sobral
Viviane Roberta Vieira Sobral
CSCamila Morais Gonçalves da Silva
Camila Morais Gonçalves da Silva
FGFrancisco Carlos Groppo
Francisco Carlos Groppo
To characterize liposomal-lidocaine formulations for topical use on oral mucosa and to compare their in vitro permeation and in vivo anesthetic efficacy with commercially available lidocaine formulations. Large unilamellar liposomes (400 nm) containing lidocaine were prepared using phosphatidylcholine, cholesterol, and α-tocoferol (4:3:0.07, w:w:w) and were characterized in terms of membrane/water partition coefficient, encapsulation efficiency, size, polydispersity, zeta potential, and in vitro release. In vitro permeation across pig palatal mucosa and in vivo topical anesthetic efficacy on the palatal mucosa in healthy volunteers (double-blinded cross-over, placebo controlled study) were performed. The following formulations were tested: liposome-encapsulated 5% lidocaine (Liposome-Lido5); liposome-encapsulated 2.5% lidocaine (Liposome-Lido2.5); 5% lidocaine ointment (Xylocaina®), and eutectic mixture of lidocaine and prilocaine 2.5% (EMLA®). The Liposome-Lido5 and EMLA showed the best in vitro permeation parameters (flux and permeability coefficient) in comparison with Xylocaina and placebo groups, as well as the best in vivo topical anesthetic efficacy. We successfully developed and characterized a liposome encapsulated 5% lidocaine gel. It could be considered an option to other topical anesthetic agents for oral mucosa.

1 October 2016 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
LSLuciano Serpe
Luciano Serpe
AJAmit Jain
Amit Jain
CMCristina Gomes de Macedo
Cristina Gomes de Macedo
MVMaria Cristina Volpato
Maria Cristina Volpato
FGFrancisco Carlos Groppo
Francisco Carlos Groppo
Michelle Franz-MontanMichelle Franz-Montan
Michelle Franz-Montan

10 July 2004 in British Dental Journal
Verified
Journal Article
Closed access
POP C Oliveira
P C Oliveira
MVM C Volpato
M C Volpato
JRJ C Ramacciato
J C Ramacciato
JRJ Ranali
J Ranali

1 June 2007 in Anesthesia & Analgesia
Verified
Journal Article
Closed access
Michelle Franz-MontanMichelle Franz-Montan
Michelle Franz-Montan
ASAndré L. R. Silva
André L. R. Silva
KMKarina Cogo Müller
Karina Cogo Müller
CBCristiane de C. Bergamaschi
Cristiane de C. Bergamaschi
MVMaria C. Volpato
Maria C. Volpato
Francisco GroppoFrancisco Groppo
Francisco Groppo
The elimination of pain caused by needle insertion for local anesthesia would be a significant advance in dentistry. In this blinded cross-over study we evaluated the efficacy of liposome-encapsulated ropivacaine for topical anesthesia. Thirty healthy volunteers received 60 mg topical anesthetics: Liposome-encapsulated 1% ropivacaine, 1% plain ropivacaine, 2.5% lidocaine and 2.5% prilocaine mixture (EMLA), and 20% benzocaine gel, in the buccal fold of the upper-right canine for 2 min in different sessions. After insertion of 30-G needles, pain was rated on a visual analog scale (VAS). A pinprick test was used to measure the duration of topical anesthesia. The pulpar response was assessed by an electric pulp tester. VAS median and interquartile range (in cm) were 0.8 (0.4-1.5), 1.6 (0.8-2.6), 1.1 (0.3-2.7), 2.2 (0.9-2.9) for liposome-encapsulated ropivacaine, ropivacaine, EMLA, and benzocaine groups, respectively. The liposome-encapsulated ropivacaine group showed lower VAS mean values when compared with the benzocaine group (P = 0.0205). The median values and interquartile range for the duration of soft tissue anesthesia were 11 (7-14), 6.5 (4-11), 14 (11-16), and 7 (6-9) min for liposome-encapsulated ropivacaine, ropivacaine, EMLA, and benzocaine groups, respectively. EMLA and liposome-encapsulated ropivacaine were just as efficient for reducing pain, and showed longer soft tissue anesthesia when compared to the other local anesthetics (P = 0.0001). Liposomal-encapsulated 1% ropivacaine gel was equivalent to EMLA for reducing pain during needle insertion and for the duration of soft tissue anesthesia. None of the topical anesthetics was effective for inducing pulpal anesthesia.